DAPA-HF One Year on: What Have You Missed?

Published: 31 July 2020

  • Views:

    Views Icon 48
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.

Agenda

  • Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
  • Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
  • DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
  • Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
  • Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)

More from this programme

Part 1

Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF

Part 2

Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF

Part 3

DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF

Part 4

Impact of Dapagliflozin Treatment on KCCQ

Part 5

Dapagliflozin and Diuretic Use in Patients With HFrEF

Faculty Biographies

Scott Solomon

Scott Solomon

Director, Noninvasive Cardiology / Professor

Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction. 

He received his AB from Williams College and his MD from Harvard Medical School. 

View full profile